Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2017 Nov 30;7:16646. doi: 10.1038/s41598-017-16816-1

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Panpan Lu 1, Yinzhong Shen 2, He Yang 1, Yanan Wang 1, Zhengtao Jiang 1, Xinyi Yang 1, Yangcheng Zhong 1, Hanyu Pan 1, Jianqing Xu 2, Hongzhou Lu 2, Huanzhang Zhu 1,✉
PMCID: PMC5709369  PMID: 29192216

Abstract

Persistent latent reservoir in resting CD4+ T cells is a major obstacle in curing HIV-1 infection. Effective strategies for eradication of the HIV-1 reservoir are urgently needed. We report here for the first time that two BET inhibitors, RVX-208, which has entered phase II clinical trials for diverse cardiovascular disorders, and PFI-1, which has been widely studied in oncology, can reactivate HIV-1 from latency. RVX-208 and PFI-1 treatment alone or in combination with other latency reversing agents efficiently reactivated HIV-1 transcription through an up-regulation of P-TEFb by increasing CDK9 Thr-186 phosphorylation in latently infected Jurkat T cells in vitro. The two BET inhibitors also reactivated HIV-1 transcription in cART treated patient-derived resting CD4+ T cells ex vivo, without influence on global immune cell activation. Our findings, in combination with previous reports, further confirm that BET inhibitors are a group of leading compounds for combating HIV-1 latency for viral eradication.

Introduction

The introduction of combination antiretroviral therapy (cART) represents a groundbreaking achievement in the effort to combat human immunodeficiency virus-1 (HIV-1) infection, and provides clinicians with a therapeutic opportunity to suppress viral replication and restore the immune function of infected individuals1,2. However, long-term cART does not result in HIV-1 eradication because of the presence of long-lived viral reservoirs. cART cessation results in viral rebound within weeks that arises from resting memory CD4+ T cells harboring HIV-1 proviral DNA integrated into the cellular genome3–5. Therefore, the development of therapies capable of exhausting this latent viral reservoir, primarily residing within long-lived CD4+ T cells, has become a highly prioritized goal in HIV-1 research.

One approach towards this aim, often referred to as ‘shock and kill’6, is characterized by the use of pharmacological agents to reverse HIV-1 latency and turn on the production of viral proteins in latently infected cells, as this would theoretically expose such cells to killing by immune-mediated mechanisms or viral cytopathic effects. A wide range of latency reversing agents (LRAs) has been investigated in vitro and ex vivo 7 with a few candidates being advanced to testing in experimental clinical trials8–10. These can be categorized into the following groups, mainly based on pharmacological targets: (1) histone deacetylase inhibitors (HDACi); (2) cytokines and chemokines; (3) DNA methyltransferase inhibitors (DNMTi); (4) histone methyltransferase inhibitors (HMTi); (5) protein kinase C (PKC) activators; (6) positive transcription elongation factor b (P-TEFb) activators; and (7) unclassified agents, such as disulfram7,11. However, all these interventions have still not shown any durable decrease in the viral reservoir, and toxicity and target specificity still remain major concerns.

Bromodomains have emerged as attractive candidates for the development of inhibitors targeting gene transcription. Inhibitors of the bromodomain and extra terminal (BET) family recently showed promising activity in diverse disease models12. Notably, our and other laboratories have proved that some BET inhibitors including OTX01513, JQ114,15 and UMB-13616 could induce latent HIV-1 expression in diverse cell culture models and patient-derived resting CD4+ T cells. RVX-208 is a first-in-class, oral BET inhibiror, also known as RVX000222, in development by Resverlogix Corporation (Calgary, AB, Canada) for the treatment of acute coronary syndromes, atherosclerosis17,18 and Alzheimer’s disease19. This novel small molecule is currently in Phase II clinical trials and the evidence indicates that RVX-208 increases apolipoprotein AI (ApoA-I) and high-density lipoprotein cholesterol (HDL-C) levels as potential therapeutic targets for reducing atherosclerotic disease, in non-human primates and humans17,20. The dihydroquinazolinone PFI-1, also named as PF-6405761, has recently been reported as a BET chemical probe derived from optimization of a fragment-screening hit21. PFI-1 exhibits activity against cell lines carrying oncogenic rearrangements in the MLL locus. The compound causes significant down-regulation of Aurora B kinase with a decrease in phosphorylation of the Aurora substrate histone 3 S10 (H3S10)22,23. The present study explores the ability of the two BET inhibitors to target latent HIV-1 in latently infected Jurkat T cell culture models in vitro as well as patient-derived resting CD4+ T cells ex vivo. Our results for the first time identify RVX-208 and PFI-1 as potential candidates of anti-HIV-latency therapy.

Results

RVX-208 and PFI-1 are potent activator of HIV-1 in different in vitro Jurkat T models of latency

Figure 1A displays the structure of RVX-208 and PFI-1. To determine the effect of RVX-208 and PFI-1 on latent HIV-1 reactivation, we used J-Lat C11 cell line in which transcriptional activation of the latent provirus can be detected in individual cells by flow cytometry, since these cells harbor full-length latent HIV-1 provirus containing GFP gene in place of nef 13,24–27. We found that both RVX-208 and PFI-1 robustly increased the level of GFP expression. 75% GFP-expressing cells were detected at 100 μM of RVX-208 and 89% GFP-expressing cells were determined at 10 μM of PFI-1 in C11 culture models at 72 hours. JQ1 was done as a positive control, which has been widely reported to reactivate latent HIV-114,15,28. Only a small number of cells expressed GFP in DMSO treated group (Fig. 1B). Furthermore, we found that the effects of the two BET inhibitors on reactivation were dose- and time-dependent (Fig. 2A,B). Cytotoxicity measurements under similar conditions demonstrated that RVX-208 and PFI-1 caused minimal cellular toxicity and had minor effects on cell proliferation (Supplementary Fig. 1A,B).

Figure 1.

Figure 1

Open in a new tab

In vitro activation of HIV-1 expression by BET inhibitors in Jurkat C11 cell culture models. (A) The molecular structure of RVX-208 and PFI-1. (B) Induction of GFP expression by 50 μM RVX-208, 5 μM PFI-1 and 1 μM JQ1. Flow cytometry analysis of C11 cells is shown.

Figure 2.

Figure 2

Open in a new tab

In vitro activation of HIV-1 expression by BET inhibitors in diverse Jurkat T cell culture models. (A and C) A dose response of HIV-1 activation by BET inhibitors was determined by the quantification of GFP reporter activity after a 72-hour treatment in C11 cells (A) or A10.6 cells (C). (B and D) Time course of the induction of GFP expression by BET inhibitors. C11 cells (B) or A10.6 cells (D) were treated with 50 μM RVX-208, 5 μM PFI-1 or 1 μM JQ1 for 24 to 72 hours. Percentage of GFP-positive cells was determined by flow cytometry.

In addition to C11 cells, the two BET inhibitors also can induce latent HIV-1 expression as a function of dose and time (Fig. 2C,D) in the presence of minimal cellular toxicity (Supplementary Fig. 1C,D) in A10.6 cells, another Jurkat-based post-integrative latency model developed in Eric Verdin’s laboratory29. In summary, these data show that both RVX-208 and PFI-1 are effective in inducing the expression of latent HIV-1 in Jurkat T cell culture models in vitro.

RVX-208 and PFI-1 activate latent HIV-1 ex vivo in resting CD4+ T cells from virally suppressed patients

Latently infected resting CD4+ T cells represent the major reservoir for HIV-1. We therefore examined whether RVX-208 and PFI-1 treatment also correlated with HIV-1 reactivation in resting CD4+ T cells isolated from patients chronically infected with HIV-1 who were treated with cART. Isolated resting CD4+ T cells were treated with LRAs for 18 hours and cell-associated viral RNA levels were analyzed using primers specific for the HIV-1 3′ polyadenylation (poly A) region. After treatment with RVX-208, increase in HIV-1 full-length transcripts was observed in all five donors, four of which showed >2-fold induction. After treatment with PFI-1, HIV-1 transcripts increasing was observed in two of three donors, the two showed >2-fold induction. SAHA treatment induced an increase in four of five donors, two showed >2-fold induction. Prostratin only increased HIV-1 transcription in three of five donors, one showed a 1.7 fold and another showed a 1.9 fold induction (Fig. 3A).

Figure 3.

Figure 3

Open in a new tab

Ex vivo activation of HIV-1 expression by RVX-208 and PFI-1. (A) Resting CD4+ T cells were isolated from virally suppressed HIV-1-infected patients and pulse-treated with prostratin (1 μM), SAHA (0.5 μM), RVX-208 (50 μM) or PFI-1 (5 μM) for 18 hours. Cell-associated total RNA was extracted, HIV-1 RNA levels were quantified using RT-qPCR for the Poly A region, and fold increase was determined relative to DMSO control. *p < 0.05, **p < 0.01. (B) Resting CD4+ T cells isolated from another two HIV-1 patients were treated with PHA (5 μg/ml), RVX-208 (50 μM) or PFI-1 (5 μM) and viral RNA was quantified in cell culture supernatant 18 hours after the addition of drugs. Results are depicted as fold increase in viral RNA relative to control cultures.

We next examined whether RVX-208 and PFI-1 induce the release of HIV-1 particles from patient-derived resting CD4+ T cells. We used HIV-1 RNA in cell culture supernatants as a marker for virion release from treated cells. Resting CD4+ T cells from two patients were treated RVX-208 or PFI-1 for 18 hours and the level of supernatant HIV-1 RNA were analyzed using primers specific for the HIV-1 gag gene. RVX-208 treatment induced an increase in the supernatant of cell cultures in both two donors, PFI-1 treatment induced an increase in one of the two donors. PHA treatment was conducted as a positive control (Fig. 3B).

Cytotoxicity measurements were performed in PBMCs to determine the effects of the two BET inhibitors on cell viability and cell proliferation. Results indicated that the 50% cytotoxic concentration (CC50) of both RVX-208 and PFI-1 were more than 200 μM, higher than the active concentrations (Supplementary Fig. 2). These results certify the potential of RVX-208 and PFI-1 as candidates of LRAs.

Combined treatments of RVX-208 and PFI-1 with either prostratin or TNFα synergistic activate latent HIV-1

Combinations of mechanistically distinct LRAs may be necessary to overcome the multiple mechanisms governing HIV-1 latency. We therefore measured the synergism of RVX-208 and PFI-1 with other LRAs in latently infected C11 cell culture models. C11 cells were stimulated with either single BET inhibitors, or in combination with the protein kinase C (PKC) activator prostratin (0.2 μM) and the proinflammatory cytokine TNFα (10 ng/ml) for 72 hours. Lower concentrations were used in these assays to more obviously observe the combined effect. As shown in Fig. 4A, RVX-208 (5 μM) treatment alone only stimulated 12% GFP expression in C11 cells. When combined with prostratin or TNF-α, the effect of RVX-208 on reactivation became robust and displayed as 82% and 35%, respectively. PFI-1 (0.1 μM) treatment alone induced 10% GFP expression, and the effect of PFI-1 became 83% and 23% when in combination with prostratin and TNF-α respectively (Fig. 4A). Cytotoxicity measurements demonstrated that there were no effects on cell viability and proliferation when the two BET inhibitors were combined with other LRAs. (Supplementary Fig. 3).

Figure 4.

Figure 4

Open in a new tab

Synergetic activation of HIV-1 expression by BET inhibitors combined with other LRAs. (A) C11 cells were incubated with either single BET inhibitors or in combination with prostratin or TNFα for 72 hours. Percentage of GFP-expressing cells was determined by flow cytometry. (B) Calculation of synergy for LRA combinations using the Bliss independence model. Data are presented as the difference between the observed and predicted effects. See Methods for more details.

To quantitate whether these combined effects meet criteria for drug synergy, the experimentally observed combined effects was compared to the effects predicted under the Bliss independence model for combined drug effects30,31. Effects of combinations that are greater than the idealized Bliss independence prediction imply synergy. We found that the two BET inhibitors synergize significantly with prostratin and TNF-α (Fig. 4B).

RVX-208 and PFI-1 neither induce global activation of immune cells nor increase cell surface expression of HIV-1 receptors

LRAs suitable for therapeutic use should not induce nonspecific immune activation. To determine whether RVX-208 and PFI-1 led to the cellular activation, primary CD4+ T cells isolated from healthy individuals were treated with RVX-208, PFI-1 or prostratin for 72 hours. The activation status was assessed by flow cytometry analysis of the cell surface activation markers including CD25, CD69 and HLA-DR. We observed that RVX-208 treatment did not cause any upregulation of T cell activation markers. Conversely, prostratin treatment robustly induced the surface expression of CD25 and CD69 in CD4+ T cells, which is consistent with previously published results32 (Fig. 5). Furthermore, we assessed the CD4+ T cells apoptosis by flow cytometry with Annexin V and PI staining, which could recognize the early and late apoptotic cells respectively, and found the two BET inhibitors make no effect on cell apoptosis (Supplementary Fig. 4).

Figure 5.

Figure 5

Open in a new tab

RVX-208 and PFI-1 do not induce global activation of CD4+ T cells. (A and B) CD4+ T cells isolated from healthy donors were treated with prostratin (1 μM), RVX-208 (50 μM) or PFI-1 (5 μM) and stained for surface markers 72 hours after the treatment initiation. Fractions of CD25, CD69 (A) and HLA-DR (B) positive cells were analyzed by flow cytometry. (C) The percentage of CD25, CD69 and HLA-DR positive CD4+ T cells was calculated. **p < 0.01.

CD8+ T cells might be important for clearing cells with reactivated virus, especially the HIV-1 specific response. We therefore isolated CD8+ T cells and examined the effects of RVX-208 and PFI-1 on activation and proliferation of them. We observed the same phenomenon as in CD4+ T cells that the two compounds did not induce the activation of CD8+ T cells (Fig. 6) and made no influence on cells viability and proliferation (Supplementary Fig. 5).

Figure 6.

Figure 6

Open in a new tab

RVX-208 and PFI-1 do not induce global activation of CD8+ T cells. (A and B) CD8+ T cells isolated from healthy donors were treated with prostratin (1 μM), RVX-208 (50 μM) or PFI-1 (5 μM) and stained for surface markers 72 hours after the treatment initiation. Fractions of CD25, CD69 (A) and HLA-DR (B) positive cells were analyzed by flow cytometry. (C) The percentage of CD25, CD69 and HLA-DR positive CD8+ T cells was calculated. **p < 0.01.

Drug-mediated change of HIV-1 receptors surface expression is an important factor for de novo HIV-1 infection. Prostratin was previously shown to exhibit anti-viral activity by decreasing surface expression of CD4 receptor32. We therefore assessed the expression of viral receptor CD4 and co-receptors CXCR4 and CCR5 in primary CD4+ T cells following RVX-208 or PFI-1 treatment. We demonstrated that both RVX-208 and PFI-1 treatments had no effect on the CD4, CXCR4 and CCR5 surface expression, suggesting that RVX-208 and PFI-1 do not increase the possibility of de novo HIV-1 infection. Prostratin treatment reduced the cell surface expression of CD4 receptor, which is in agreement with previously published results (Fig. 7).

Figure 7.

Figure 7

Open in a new tab

RVX-208 and PFI-1 do not up-modulate the expression of CD4, CXCR4 and CCR5 of CD4+ T cells. (A and B) CD4+ T cells isolated from healthy donors were treated with prostratin (1 μM), RVX-208 (50 μM) or PFI-1 (5 μM) and stained for surface markers 72 hours after the treatment initiation. Fractions of CD4, CXCR4 (A) and CCR5 (B) positive cells were analyzed by flow cytometry. (C) The percentage of CD4, CXCR4 and CCR5 positive cells was calculated. *p < 0.05.

In conclusion, neither global activation of CD4+ and CD8+ _T cells nor the expression of viral receptors was induced by RVX-208 and PFI-1 treatments, suggesting that these two BET inhibitors may be reliable LRA candidates for further evaluation.

HIV-1 activation by RVX-208 and PFI-1 correlate with the viral protein Tat

HIV-1 transcriptional transactivator (Tat) is essential for the synthesis of full-length transcripts from the integrated viral genome by RNA polymerase II (RNAP II). The viral Tat recruits a cellular kinase complex termed P-TEFb to the transactivator RNA (TAR) at the 5′-end of the nascent HIV-1 transcript33,34. Considered the important role for Tat in supporting HIV-1 expression and replication, we determined whether BET inhibitors’ reactivation relies on Tat. We used TZMbl cell line, which contains an integrated copy of the HIV-1 LTR with a Luciferase reporter protein. Tat transactivation assays can be readily performed in it by transfection of a Tat expression plasmid and measurement of Luciferase expression from the integrated provirus34. We found that the two BET inhibitors only slightly increased the LTR-driven luciferase expression in the absence of Tat (2.7-fold and 1.7-fold). However, when Tat was expressed, RVX-208 and PFI-1 activated the HIV-1 LTR much more potently (244-fold and 109-fold). Tat alone activated 63-fold luciferase expression (Fig. 8). This result indicates that the effect of BET inhibitors on activation of latent HIV-1 is potently enhanced in the presence of Tat in Hela-based TZMbl cells.

Figure 8.

Figure 8

Open in a new tab

The role of Tat in RVX-208 and PFI-1-mediated activation of latent HIV-1. TZMbl cells were transfected with control or Tat expressing vector, and then received RVX-208 (50 μM) or PFI-1 (5 μM) treatment. Lysates were examined for luciferase activity and depicted as fold increase relative to control.

RVX-208 and PFI-1 induce CDK9 Thr-186 phosphorylation

P-TEFb stimulates processive transcriptional elongation by phosphorylating the carboxyl terminal domain (CTD) of RNAP II and specific protein subunits of NELF and DSIF, thereby abrogating their inhibition of elongation. In latency cells, P-TEFb function is down-regulated due to low expression levels of subunit cyclin-dependent kinase 9 (CDK9) and repression of CDK9 Thr-186 (T-loop) phosphorylation, a critical posttranslational modification required for kinase activity35–37. Because P-TEFb is important for Tat-mediated HIV-1 transcription, we reasoned that the two BET inhibitors reactivation would also likely to up-regulate P-TEFb. We treated C11 cells with them and examined cell lysates for the expression of CDK9 and pCDK9 in immunoblots. There are two isoforms of the CDK9 protein - the major 42KDa CDK9 isoform and the minor 55 KDa isoform38–40. We found that there was no change for the expression level of 42KDa CDK9 isoform, but slightly increase for the 55 KDa CDK9 isoform after treatment with RVX-208 or PFI-1. Remarkably, the CDK9 Thr-186 phosphorylation was up-regulated obviously with the help of either the two BET inhibitors. Since the expression level of pCDK9 was not so much as that of CDK9, we only examined the major 42KDa pCDK9 isoform (Fig. 9). Nevertheless, our results indicate that RVX-208 or PFI-1 both promote CDK9 Thr-186 phosphorylation when reversing HIV-1 latency.

Figure 9.

Figure 9

Open in a new tab

RVX-208 and PFI-1 induce CDK9 Thr-186 phosphorylation. C11 cells were incubated with 50 μM RVX-208 (A) or 5 μM PFI-1 (B) for 24 hours, cell lysates were analyzed for the expression of CDK9 and pCDK9 in immunoblots. The grouping blots were cropped from different fields. Full-length blots are included in the Supplementary Fig. 6.

Discussion

Resverlogix is developing RVX-208 to treat cardiovascular disorders, including atherosclerosis, cerebrovascular disease and hypertension. The first-in-class compound could also be beneficial for the treatment of Alzheimer disease. Clinical development is underway in the US for atherosclerosis, acute coronary syndromes and Alzheimer disease17–20,41–45. The data from this study show for the first time that RVX-208 acts as a potent activator of latent HIV-1 with effects observed either in diverse Jurkat T latency models or in resting CD4+ T cells isolated from patients chronically infected with HIV-1 who were treated with cART. The widely concentration that RVX-208 reactivated latent HIV-1 in this study is 50 μM. Although it is much higher than the concentration of positive control JQ1, prostratin and SAHA, it is similar to those achieved in HepG2 cells receiving 60 μmol/l RVX-208 followed by assays for apoA-I and HDL-C production. In this study, clinical trial had been conducted in healthy volunteers (given 1 to 20 mg/kg/day of RVX-208) to assess safety, tolerability, and pharmacokinetics, data in humans pointed to beneficial features of RVX-208 that might be useful for treating atherosclerosis17. Given the in vitro and ex vivo results and the established clinical safety profile of RVX-20844–46, clinical testing is warranted to assess whether RVX-208 can activate latent HIV-1 and potentially reduce the size of the latent viral reservoir in cART treated HIV-infected patients.

Identified as a BET inhibitor through optimization of a fragment-derived hit, PFI-1 is chemically distinct from previously reported BET inhibitors21. The small molecular inhibitor resulted in induction of caspase-dependent apoptosis, differentiation, and in downregulation of the Aurora B kinase in leukemia cells22,23. Here, we first report that PFI-1 potently reactivates latent HIV-1 in various post-integration latency Jurkat T cell models in vitro and patient-derived resting CD4+ T cells ex vivo. Although the concentration of PFI-1 is not lower than that of the positive controls, the CC50 of it on PBMCs was more than 200 μM, much higher than the active concentrations (5 μM). These results support further investigations for PFI-1 to antagonize HIV-1 from latency.

Induction of HIV-1 expression from latent reservoirs is being pursued as a component of the reservoir eradication strategy that may ultimately lead to a prolonged drug-free remission or even cure47–49. It should be noted that both RVX-208 and PFI-1 reactivated latent HIV-1 to a little degree, which was 2.6-fold and 1.9-fold to the mock control respectively in patient-derived resting CD4+ T cells. It also should be noted that the active concentrations of both RVX-208 and PFI-1 were relatively high. Therefore, additional significant efforts would likely have to be devoted to improving the HIV-1 reactivation effects of the two BET inhibitors. As already suggested, this may potentially be achieved by combining BET inhibitors with other LRAs that work through complementary mechanisms. Here, we documented the synergistic effects on HIV-1 expression between the two BET inhibitors and the PKC activator prostratin or the proinflammatory cytokine TNFα in vitro. In future studies, more classes of LRAs should be considered for testing in combination with the two BET inhibitors to identify potential synergies for HIV-1 reactivation ex vivo or in vivo.

Among the characteristics necessary for clinically testable LRAs, toxicity is a crucial concern. The major problem with present LRAs is the nonspecific induction of many genes and the toxicity caused by the systematic release of cytokines. Ideal LRAs for shock and kill strategies should reverse HIV-1 from latency without causing broad and robust T cell activation11,50. Our present data demonstrated that RVX-208 and PFI-1 do not elevate expression levels of CD25, CD69 or HLA-DR, and do not upregulate CD4, CXCR4 or CCR5. We and others have previously reported that BET inhibitors OTX015, JQ1 and UMB-136 exhibit activity to antagonize HIV-1 latency in the absence of global T cell activation13,16,28. Generally, given the potency and minimal toxicity, BET inhibitors will be a group of promising candidates for future therapy against reactive latent HIV-1.

HIV-1 replication is dependent on activation of RNAP II by the viral Tat protein. Following transcription initiation from the HIV-1 LTR, RNAP II pauses due to the action of two negative elongation factors, NELF and DSIF, which associate with the RNAP II complex. To activate elongation, Tat recruits P-TEFb to the TAR RNA element at the 5′ end of the nascent viral transcript. Core P-TEFb consists of CDK9 and the regulatory subunit Cyclin T1. P-TEFb stimulates processive transcriptional elongation by phosphorylating the Ser2 residues of the CTD of RNAP II, as well as NELF and DSIF, thereby abrogating their inhibition of elongation37,51,52. Thus, viral Tat and cellular P-TEFb levels are key regulators that operate in the context of multiple host factors to influence latency and viral reactivation28. Based on the data presented here, we propose that RVX-208 and PFI-1 induce latent HIV-1 expression likely in part through an up-regulation of P-TEFb by increasing CDK9 Thr-186 phosphorylation, and Tat is important in BET inhibitors-mediated reactivation. Also, we need to indicate here that, according to some researchers report, phosphorylation of CDK9 at Thr 186 is not only important for promoting P-TEFb kinase activity but it is also required for P-TEFb to be sequestered into the 7SK snRNP complex53. We still don’t know which BET protein RVX-208 and PFI-1 target in inducing HIV-1 expression.

In summary, we initially provide strong evidence that RVX-208 and PFI-1 are attractive potential candidates for HIV-1 cure studies. Our study in combination with previous reports suggests that BET inhibitors represent a group of leading compounds for combating HIV-1 latency for viral eradication and need further study.

Methods

Measurement of HIV-1 latency reversal in vitro

J-Lat C11 cells24,26 (established in our lab) and A10.6 cells29,54 (obtained from NIH AIDS Reagent Program) harboring latent, transcriptionally competent HIV-1 provirus that encodes GFP as an indicator of viral activation were cultured in RPMI1640 medium (Gorning) supplemented with 10% fetal bovine serum (FBS) (Gibco), 100 U/mL penicillin and 100 μg/ml streptomycin (Gibco) in a 37 °C incubator containing 5% CO2. For in vitro reactivation experiments, C11 cells or A10.6 cells were stimulated with RVX-208 (Selleckchem), PFI-1 (Selleckchem), JQ1 (Selleckchem), SAHA (Sigma-Aldrich), prostratin (Sigma-Aldrich) or TNF-α (Sigma-Aldrich) respectively and subjected to determine GFP expression using flow cytometry (BD Calibur).

Ethics statement

HIV-infected patients were enrolled into the study in Shanghai Public Health Clinical Center and written informed consent was obtained from the patients prior to any study procedures. Clinical and biological characteristics of the patients are listed in Table 1.

Table 1.

Characteristics of HIV-infected patients receiving cART.

Patients Gender Age (years) CD4+ T cell count (cells/μl) ART regimen Duration of therapy (years) Duration of viral suppression (<40 copies/ml of plasma HIV-1 RNA) (months)
1 Male 51 568 AZT + 3TC + EFV 5 39
2 Male 59 541 TDF + 3TC + LPV/R 2 14
3 Male 31 455 AZT + 3TC + NVP 8 43
4 Male 43 453 AZT + 3TC + EFV 3 27
5 Male 46 388 AZT + 3TC + EFV 4 17
6 Male 35 451 TDF + 3TC + EFV 3 30
7 Male 29 417 AZT + 3TC + EFV 4 40
Open in a new tab

Note: AZT, Zidovudine; 3TC, lamivudine; EFV, efavirnez; TDF, tenofovir; LPV/R, Lopinavir/Ritonavir; NVP, nevirapine.

Primary cells isolation

These assays were approved by Shanghai Public Health Clinical Center and Shanghai Changhai Hospital. Peripheral blood mononuclear cells (PBMCs) were isolated from fresh whole blood by density gradient centrifugation using Lympholyte®-H Cell Separation Media (Cedarlane Laboratories) as previously described13,27. CD4+ T cells were isolated from PBMCs by negative selection using CD4+ T cell Isolation Kit (Miltenyi Biotech). Resting CD4+ T cells were isolated from CD4+ T cells by depletion of cells expressing CD69, CD25 or HLA-DR using CD25-Biotin, CD69-Biotin and HLA-DR-Biotin antibody-coated magnetic beads (Miltenyi Biotech). CD8+ T cells were isolated from PBMCs by positive selection using CD8 MicroBeads (Miltenyi Biotech).

Measurement of HIV-1 latency reversal ex vivo

These assays were modified from Shan et al.55,56 and approved by Shanghai Public Health Clinical Center. Resting CD4+ T cells (5 × 106) isolated from HIV-infected patients were stimulated with different LRAs for 18 hours under 10 μM T20 treatment. Total RNA was isolated using the ZR-96 Viral RNA Kit (Zymo Research). cDNA was synthesized from the isolated RNA using the the GoScript Reverse Transcription System (Promega) with oligo(dT)15 primers. Isolated cDNA was assayed for HIV-1 by RT-PCR using the QuantiFast SYBR Green PCR Kit (QIAGEN) on a Roche LightCycler 480 II machine. Primers used for detecting intracellular RNA were specific for the HIV-1 3′ poly A region: forward (5′-3′) CAGATGCTGCATATAAGCAGCTG and reverse (5′-3′) TTTTTTTTTTTTTTTTTTTTTTTTGAAGCAC. Primers used for detecting supernatant RNA were specific for the HIV-1 gag gene: forward (5′-3′): ATCAATGAGGAAGCTGCAGAA and reverse (5′-3′) GATAGGTGGATTATGTGTCAT. The cycling parameters were as follows: (i) 2 minutes at 50 °C; (ii) 10 minutes at 95 °C; and (iii) 50 cycles at 95 °C for 15 s and then 60 °C for 60 s. Each sample was tested in triplicate, and results were normalized with the human TATA-binding protein (TBP) gene.

Quantitative analysis of synergy of latency reversing agent combinations

We adapted the Bliss independence model as implemented by Laird et al. to test for synergy when BETi was combined with other LRAs30,31. For drugs x and y, we used the equation fa xy,P = fa x + fa y − (fa x)(fa y ), where fa xy,P represents the predicted fraction affected by the combination of drug x and drug y given the observed effects of drug x (fa x) and drug y (fa y) used individually and fa xy,O = the observed effect when x and y were tested together. Calculation of fa x as follows: fa x = %GFP positive cells with drug x − background with DMSO. With this model, Δfa xy = fa xy,O (the observed fraction affected by the drug combination) − fa xy,P (the predicted fraction affected by the drug combination) provides an indication of synergy (Δfa xy > 0), Bliss independence (Δfa xy = 0) or antagonism (Δfa xy < 0).

Cytotoxicity assay

This assay was performed as the manufacturer’s protocol of the Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies) and approved by Shanghai Changhai Hospital. Briefly, approximately 4 × 104 cells per well were treated with different LRAs at the indicated concentrations for the indicated time, and then 10 μl of CCK-8 solution was added to each well. After 4 hours of incubation at 37 °C, the absorbance at 450 nm was measured using a microplate reader.

Apoptosis Assay

This assay was performed according to the guideline of the Annexin V, FITC Apoptosis Detection Kit (Dojindo Molecular Technologies) and approved by Shanghai Changhai Hospital. Briefly, after incubated with LRAs for 72 hours, primary CD4+ T cells isolated from healthy donors were immunostained with FITC conjunct Annexin V and PI solution for 15 minutes and subjected to flow cytometry analysis.

Cell activation analysis

This assay was performed according to the guidelines of BD Pharmingen and approved by Shanghai Changhai Hospital, primary CD4+ T cells or CD8+ T cells isolated from blood of healthy donors were stimulated with different LRAs for 72 hours and then stained with CD25-PE, CD69-FITC and HLA-DR-PE antibodies (BD Biosciences) to subject to flow cytometry analysis.

HIV-1 receptors’ expression analysis

This assay was performed according to the guidelines of BD Pharmingen and approved by Shanghai Changhai Hospital, primary CD4+ T cells isolated from blood of healthy donors were stimulated with different LRAs for 72 hours and then stained with CD4-PE, CXCR4-FITC and CCR5-FITC antibodies (BD Biosciences) to subject to flow cytometry analysis.

Luciferase assay

Hela-based TZMbl cells containing an integrated HIV-1 LTR-luciferase reporter construct were obtained from NIH AIDS Reagent Program (Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc.) and cultured in Dulbecco’s modified Eagle’s medium (DMSO) (Gorning) supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/ml streptomycin in a 37 °C incubator containing 5% CO2. For luciferase assay, TZMbl cells were transfected with Tat or pcDNA 3.1 plasmid using Lipofectamine 3000 Reagent (Invitrogen) 24 hours before the drug treatment. Cells were then treated with LRAs for 48 hours and subjected to determine luciferase activity using Dual-Luciferase Reporter Assay Kit (Promega).

Western Blotting

As previously described13,57, C11 cells were pulse-treated with LRAs for 24 hours and then lysed in buffer containing 50 mM Tris–HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1 mM DTT, 0.1% SDS, 1% Nonidet P-40, 1 mg/ml leupeptin and soybean trypsin inhibitor, 0.5 mM PMSF on ice for 30 minutes. Approximately 50–150 mg of thermally denatured cellular lysates was used for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) immunoblotting analysis. The primary antibodies used were anti-CDK9 and anti-CDK9-pT186 (Cell Signaling Technology). Immunoblotting bands were quantified using the ECL Western blotting system (Santa Cruz Biotechnology).

Statistical analysis

Data are representative of at least 3 independent experiments, and error bars represent standard deviation. The two-tailed unpaired Student t test was adopted to analyze the data sets, where p < 0.05 was considered statistically relevant.

Electronic supplementary material

Supplementary Dataset (1.9MB, doc)

Acknowledgements

This work was funded by National Natural Science Foundation of China (81761128020), National Natural Science Foundation of China (31771484) and National Grand Program on Key Infectious Disease (2017ZX10202102-002).

Author Contributions

P.L. performed the experiments with assistance from H.Y., Y.W., Z.J., X.Y., Y.Z. and H.P.; Y.S. provided human samples; P.L. analyzed the data and wrote the manuscript; H.Z. supervised the project. All authors reviewed the manuscript.

Competing Interests

The authors declare that they have no competing interests.

Footnotes

Electronic supplementary material

Supplementary information accompanies this paper at 10.1038/s41598-017-16816-1.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Gulick RM, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739. doi: 10.1056/NEJM199709113371102. [DOI] [PubMed] [Google Scholar]
  • 2.Perelson AS, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188–191. doi: 10.1038/387188a0. [DOI] [PubMed] [Google Scholar]
  • 3.Chun TW, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193–13197. doi: 10.1073/pnas.94.24.13193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. doi: 10.1126/science.278.5341.1295. [DOI] [PubMed] [Google Scholar]
  • 5.Wong JK, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291–1295. doi: 10.1126/science.278.5341.1291. [DOI] [PubMed] [Google Scholar]
  • 6.Deeks SGHIV. Shock and kill. Nature. 2012;487:439–440. doi: 10.1038/487439a. [DOI] [PubMed] [Google Scholar]
  • 7.Shang HT, et al. Progress and challenges in the use of latent HIV-1 reactivating agents. Acta Pharmacol Sin. 2015;36:908–916. doi: 10.1038/aps.2015.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rasmussen TA, Tolstrup M, Sogaard OS. Reversal of Latency as Part of a Cure for HIV-1. Trends Microbiol. 2016;24:90–97. doi: 10.1016/j.tim.2015.11.003. [DOI] [PubMed] [Google Scholar]
  • 9.Spivak AM, Planelles V. HIV-1 Eradication: Early Trials (and Tribulations) Trends Mol Med. 2016;22:10–27. doi: 10.1016/j.molmed.2015.11.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Delagreverie HM, et al. Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis. 2016;3:ofw189. doi: 10.1093/ofid/ofw189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Xing S, Siliciano RF. Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today. 2013;18:541–551. doi: 10.1016/j.drudis.2012.12.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Garnier JM, Sharp PP, Burns CJ. BET bromodomain inhibitors: a patent review. Expert Opin Ther Pat. 2014;24:185–199. doi: 10.1517/13543776.2014.859244. [DOI] [PubMed] [Google Scholar]
  • 13.Lu P, et al. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb. Sci Rep. 2016;6:24100. doi: 10.1038/srep24100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Li Z, Guo J, Wu Y, Zhou Q. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 2013;41:277–287. doi: 10.1093/nar/gks976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Boehm D, et al. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle. 2013;12:452–462. doi: 10.4161/cc.23309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Huang H, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Front Microbiol. 2017;8:1035. doi: 10.3389/fmicb.2017.01035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Bailey D, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580–2589. doi: 10.1016/j.jacc.2010.02.035. [DOI] [PubMed] [Google Scholar]
  • 18.Nicholls SJ, et al. ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies. Cardiovasc Drugs Ther. 2012;26:181–187. doi: 10.1007/s10557-012-6373-5. [DOI] [PubMed] [Google Scholar]
  • 19.McNeill E. RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases. Curr Opin Investig Drugs. 2010;11:357–364. [PubMed] [Google Scholar]
  • 20.Jahagirdar R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236:91–100. doi: 10.1016/j.atherosclerosis.2014.06.008. [DOI] [PubMed] [Google Scholar]
  • 21.Fish PV, et al. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012;55:9831–9837. doi: 10.1021/jm3010515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Picaud S, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013;73:3336–3346. doi: 10.1158/0008-5472.CAN-12-3292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Gopalakrishnan R, et al. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35:1797–1810. doi: 10.1038/onc.2015.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ding D, et al. Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. Virology. 2013;440:182–189. doi: 10.1016/j.virol.2013.02.022. [DOI] [PubMed] [Google Scholar]
  • 25.Wang, P. et al. As2O3 synergistically reactivate latent HIV-1 by induction of NF-kappaB. Antiviral Res, 10.1016/j.antiviral.2013.10.010 (2013). [DOI] [PubMed]
  • 26.Qu X, et al. Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res. 2013;41:7771–7782. doi: 10.1093/nar/gkt571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang P, et al. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Sci Rep. 2017;7:9451. doi: 10.1038/s41598-017-07157-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Banerjee C, et al. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012;92:1147–1154. doi: 10.1189/jlb.0312165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003;22:1868–1877. doi: 10.1093/emboj/cdg188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Laird GM, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015;125:1901–1912. doi: 10.1172/JCI80142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jiang G, et al. Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog. 2015;11:e1005066. doi: 10.1371/journal.ppat.1005066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Biancotto A, et al. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. J Virol. 2004;78:10507–10515. doi: 10.1128/JVI.78.19.10507-10515.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Muniz L, et al. Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat. PLoS Pathog. 2010;6:e1001152. doi: 10.1371/journal.ppat.1001152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ramakrishnan R, et al. Identification of novel CDK9 and Cyclin T1-associated protein complexes (CCAPs) whose siRNA depletion enhances HIV-1 Tat function. Retrovirology. 2012;9:90. doi: 10.1186/1742-4690-9-90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Dong C, Kwas C, Wu L. Transcriptional restriction of human immunodeficiency virus type 1 gene expression in undifferentiated primary monocytes. J Virol. 2009;83:3518–3527. doi: 10.1128/JVI.02665-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ramakrishnan R, Dow EC, Rice AP. Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4(+) T lymphocytes. J Leukoc Biol. 2009;86:1345–1350. doi: 10.1189/jlb.0509309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Ramakrishnan R, Liu H, Rice AP. Short communication: SAHA (vorinostat) induces CDK9 Thr-186 (T-loop) phosphorylation in resting CD4+ T cells: implications for reactivation of latent HIV. AIDS Res Hum Retroviruses. 2015;31:137–141. doi: 10.1089/aid.2013.0288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Shore SM, Byers SA, Maury W, Price DH. Identification of a novel isoform of Cdk9. Gene. 2003;307:175–182. doi: 10.1016/S0378-1119(03)00466-9. [DOI] [PubMed] [Google Scholar]
  • 39.Liu H, Herrmann CH. Differential localization and expression of the Cdk9 42 k and 55 k isoforms. J Cell Physiol. 2005;203:251–260. doi: 10.1002/jcp.20224. [DOI] [PubMed] [Google Scholar]
  • 40.Shore SM, Byers SA, Dent P, Price DH. Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. Gene. 2005;350:51–58. doi: 10.1016/j.gene.2005.01.015. [DOI] [PubMed] [Google Scholar]
  • 41.Gilham D, et al. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. Atherosclerosis. 2016;247:48–57. doi: 10.1016/j.atherosclerosis.2016.01.036. [DOI] [PubMed] [Google Scholar]
  • 42.Joy TR. Novel HDL-based therapeutic agents. Pharmacol Ther. 2012;135:18–30. doi: 10.1016/j.pharmthera.2012.03.004. [DOI] [PubMed] [Google Scholar]
  • 43.McLure KG, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One. 2013;8:e83190. doi: 10.1371/journal.pone.0083190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nicholls SJ, et al. Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111–1119. doi: 10.1016/j.jacc.2010.11.015. [DOI] [PubMed] [Google Scholar]
  • 45.Nikolic D, et al. An evaluation of RVX-208 for the treatment of atherosclerosis. Expert Opin Investig Drugs. 2015;24:1389–1398. doi: 10.1517/13543784.2015.1083010. [DOI] [PubMed] [Google Scholar]
  • 46.Rvx 208. Drugs R D11, 207–213, 10.2165/11595140-000000000-00000 (2011).
  • 47.Richman DD, et al. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307. doi: 10.1126/science.1165706. [DOI] [PubMed] [Google Scholar]
  • 48.Siliciano JD, Siliciano RF. HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS. 2013;8:318–325. doi: 10.1097/COH.0b013e328361eaca. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Wei DG, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10:e1004071. doi: 10.1371/journal.ppat.1004071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Darcis G, et al. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1 + JQ1 and Ingenol-B + JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog. 2015;11:e1005063. doi: 10.1371/journal.ppat.1005063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Budhiraja S, et al. Cyclin T1 and CDK9 T-loop phosphorylation are downregulated during establishment of HIV-1 latency in primary resting memory CD4+ T cells. J Virol. 2013;87:1211–1220. doi: 10.1128/JVI.02413-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Jamaluddin MS, et al. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb. AIDS Res Hum Retroviruses. 2016;32:169–173. doi: 10.1089/aid.2015.0347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Mbonye UR, et al. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. PLoS Pathog. 2013;9:e1003338. doi: 10.1371/journal.ppat.1003338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001;20:1726–1738. doi: 10.1093/emboj/20.7.1726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Shan L, et al. A novel PCR assay for quantification of HIV-1 RNA. J Virol. 2013;87:6521–6525. doi: 10.1128/JVI.00006-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Bullen CK, et al. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014;20:425–429. doi: 10.1038/nm.3489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ying H, et al. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB. PLoS One. 2012;7:e48832. doi: 10.1371/journal.pone.0048832. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Dataset (1.9MB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES